Skip to search formSkip to main contentSkip to account menu

Olmesartan medoxomil

Known as: 1H-Imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester, 5-Methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate - T287346, Olmesartan Medoxomil [Chemical/Ingredient] 
A synthetic imidazole derivative prodrug with an antihypertensive property. Upon hydrolysis, olmesartan medoxomil is converted to olmesartan… 
National Institutes of Health

Related topics

Related topics

30 relations
Amlodipine 10 MG / Hydrochlorothiazide 25 MG / Olmesartan medoxomil 40 MG Oral TabletAmlodipine 10 MG / Hydrochlorothiazide 25 MG / Olmesartan medoxomil 40 MG Oral Tablet [Tribenzor]Amlodipine 5 MG / Olmesartan medoxomil 40 MG Oral Tablet [Azor]Angiotensin 2 Receptor Antagonists [MoA]

Broader (3)

Angiotensin II Type 1 Receptor BlockersAntihypertensive Agentsolmesartan

Narrower (5)

AzorBenicarCS 866Tribenzor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Development and Validation of Stability Indicating LC Method for Olmesartan Medoxomil
The present method provides the detailed description of development and validation of a simple stability indicating re- verse… 
2010
2010
Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes
Abstract Objective: The BENIFICIARY (BENIcar safety and efFICacy evaluatIon: An open-label, single-ARm, titration study in… 
2010
2010
Efficacy of an Olmesartan Medoxomil–Based Treatment Algorithm in Patients Stratified by Age, Race, or Sex
J Clin Hypertens (Greenwich). 2010;12:3–13. ©2009 Wiley Periodicals, Inc. 
2009
2009
The Effects of an Olmesartan Medoxomil–Based Treatment Algorithm on 24‐Hour Blood Pressure Levels in Elderly Patients Aged 65 and Older
This study examined the effect of olmesartan medoxomil (OM) ± hydrochlorothiazide (HCTZ) on mean 24‐hour ambulatory blood… 
2009
2009
Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics
Olmesartan medoxomil is a new angiotensin-2 receptor blocker (ARB). Its pharmacokinetics in hemodialysis patients has not been… 
2007
2007
Olmesartan Medoxomil–Induced Angioedema
Objective: To report a case of olmesartan medoxomil-induced angioedema in an angiotensin-converting enzyme (ACE) inhibitor–naïve… 
2007
2007
An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy
BackgroundLipid-related oxidative stress, such as that caused by malondialdehyde (MDA), acrolein, and 4-hydroxynonenal (4-HNE… 
Review
2006
Review
2006
Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.
Olmesartan medoxomil is a new orally active angiotensin II (Ang II) type 1 receptor antagonist. It is a prodrug and is rapidly de… 
2006
2006
The Protective Effects of Angiotensin II Blockade with Olmesartan Medoxomil on Resistance Vessel Remodeling (The VIOS study)
BackgroundThe VIOS (Vascular Improvement with Olmesartan medoxomil Study) study is a randomized, parallel study to determine the… 
Review
2006
Review
2006
Olmesartan medoxomil: a clinical review.
Blockade of the renin-angiotensin system by angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers has been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)